Primarily generic pharmaceuticals. Strategy is to provide niche and high manufacturing complexity API and generic drugs, as well as 505(b)(2) class new drugs (new route of administration, new derivatives, new use, etc.).
Six manufacturing facilities in Taiwan.
Chunghwa Chemical Synthesis & Biotech Co., Ltd.: API manufacturer
Suzhou Chunghwa Chemical & Pharmaceutical Industrial Co., Ltd. (China)
Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd. (China)
Chunghwa Yuming Healthcare Co., Ltd. (drug distribution)
Chunghwa Senior Care Co., Ltd. (seniors health care services)
Phermpep Co., Ltd. (peptide-based products for health)
Tai Rung Development Co., Ltd. (packaging products, ampoules, etc.)
Uses proprietary vaccine platforms to develop animal vaccine products.
Lead product PRRSFREE vaccine is the world’s first commercial subunit vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS).
Veterinary pharmaceutical company. Developed Antican, a novel anticancer drug for companion animal use, tested across multiple animal species in preclinical stage, passed Taiwanese COA New Drug Committee (similar to FDA CVM in the US).
Generic drug company.
[From website] Manufactures and markets approximately 700 products, including human drugs, veterinary drugs, cosmeceutical products, health supplements, API, and fine chemicals. Human drugs and veterinary drugs cover 87% total business volume, followed by 9% and 4% for health supplements and the other products respectively.